MMJ Phytotech is a pioneer in the development of
markets that have regulated medical cannabis laws


MMJ Phytotech News

Cannabidiol capsules Phase 1 clinical trial published

Results from the Phase 1 Clinical Trial have been published.  The article “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology” has been published in an international, peer-reviewed medical journal, Clinical Pharmacology in Drug Development. This clinical trial was completed in March 2016, and demonstrated the […]

Posted in research notes |

World Anti-Doping Agency removes Cannabidiol from banned substances list

The World Anti-Doping Agency (WADA) has announced that it is removing cannabidiol from its list of banned substances in 2018. Since 2004, and as mandated by World Anti-Doping Code, WADA has published an annual List of Prohibited Substances and Methods (List).The List, which forms one of the five International Standards, identifies the substances and methods prohibited in- […]

Posted in news |

News from Canada – approval to sell

United Greeneries has received the amendment to their sales licence from Health Canada that permits sale of dried marijuana to registered patients under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). United Greeneries has previously received the authorisation to cultivate cannabis under the ACMPR in June 2016 and commenced growing operations in December 2016, […]

Posted in announcements |

Banyan Tree Investment Report on MMJ

In a new investment report, Banyan Tree Investment Group discusses key investment drivers for MMJ Phytotech and highlights the unique investment proposition the company offers to investors. Click here to read the full report. Facebook2Twitter0Google plus0Linkedin0X

Posted in research notes |

News from Canada: 58 Licensed Producers approved

Canada has recently approved four more licensed medical cannabis companies, bringing the total number of Licensed Producers to 58. Canadian regulators implemented new rules at the end of May to streamline the licensing process, to ease the backlog of applicants (428 as of May 25) and boost cannabis production nationwide. As a result, 14 cultivation […]

Posted in news |

CannabisAccess launches initiative to help doctors prescribing medicinal cannabis

CannabisAccess is a new online portal and resource for doctors. It is designed to help them navigate the medicinal cannabis regulatory maze and make it easier for them to be in a position to prescribe medicinal cannabis to their patients. Doctors face two key issues when responding to patients who may benefit from medicinal cannabis: […]

Posted in general |

Phase 2 Epilepsy Clinical Trial Update

PhytoTech Therapeutics’ first Phase 2 clinical trial, which commenced in February 2017, is continuing as planned. This clinical trial is an open-label study aimed at evaluating the safety, tolerability and efficacy of oral administration of PTL101 as an adjunctive treatment for children with refractory epilepsy. The PTL101 drug beads are utilising proprietary formulation developed through […]

Posted in research notes |

MMJ Phytotech quarterly report released

MMJ PhytoTech Limited has released the quarterly activities report for the period ended 30 June 2017 Facebook0Twitter0Google plus0Linkedin0X

Posted in announcements |

Satipharm Scholarship announced

Satipharm is partnering with Cann10 Australia, the country’s first medicinal cannabis training company, to support the Cann10 Medicinal Cannabis Leadership Program. The Satipharm Scholarship provides a fully paid position for one participant in the 2017 Program.  The Cann10 program is a comprehensive, Australian-specific course where participants gain the knowledge, skills and professional networks they need to […]

Posted in news |

United Greeneries applies for sales licence

United Greeneries has submitted an application for a sales licence to Health Canada following the requisite two successful harvests and had its licence for the Duncan Facility renewed for 3 years. Read the company’s recent ASX announcement. Facebook1Twitter0Google plus0Linkedin0X

Posted in announcements |

Media Enquiries

Sam Burns

Account Director

Six Degrees Investor Relations

+61 (0) 400 164 067

[email protected]